Alkermes has decided to expand the number of retail pharmacies and clinics where patients can receive access to Aristada (aripiprazole lauroxil) and Vivitrol (naltrexone extended-release injectable suspension).
The expansion is aimed at making access to these treatments easier during the coronavirus disease 2019 (COVID-19) pandemic. Aristada is an injectable atypical antipsychotic approved for the treatment of schizophrenia in adults. Vivitrol is an extended-release injectable suspension containing naltrexone, an opioid antagonist. It is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting and also for the prevention of relapse to opioid dependence, following opioid detoxification.
The Company has added over 900 on-site retail pharmacy locations at certain Albertsons Companies locations throughout the US where patients can receive the medications. This includes Albertsons, Acme, Jewel-Osco, Pavilions, Randalls, Safeway, Tom Thumb, Shaw’s, Star Markets and Vons. Pharmacists at these newly designated locations are now available to provide injections of Aristada and Vivitrol.
Additionally, the Company’s Patient Access Services staff are available to help verify insurance coverage and connect patients with healthcare professionals who are providing treatment during the pandemic. In addition, Alkermes has a patient assistance program for eligible patients who meet certain criteria, including those who may be facing financial hardship because of the COVID-19 pandemic.
“In these challenging and uncertain times, it is critical that we continue to support people living with opioid dependence, alcohol dependence and schizophrenia,” said Richard Pops, Chief Executive Officer of Alkermes. “As COVID-19 and efforts to contain its spread impact access to care for some patients, we are committed to helping assure that patients have access to the medications that may help them.
For more information visit Alkermes.com.
This article originally appeared on MPR